The phase 1b NIVIPIT trial shows that in combined therapy with intravenous nivolumab (anti-PD1), intratumoural administration of ipilimumab (anti-CTLA4) offers improved safety and greater efficacy compared with intravenous delivery.
The Verdict
ClassificationLikely AI
ConfidenceHigh confidence
Analyzedtext, image
ImageAI Generated
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/e904a05e-1ea5-4daf-afc6-358dc8f4ba27)